Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Repare Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
RPTX
Nasdaq
8731
https://www.reparerx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Repare Therapeutics Inc
Repare Therapeutics Full Year 2023 Earnings: Misses Expectations
- Mar 1st, 2024 10:11 am
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
- Feb 29th, 2024 12:05 pm
Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023
- Feb 28th, 2024 12:36 pm
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Feb 28th, 2024 12:05 pm
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
- Feb 20th, 2024 3:00 pm
We're Keeping An Eye On Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Rate
- Feb 17th, 2024 2:50 pm
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
- Feb 15th, 2024 12:05 pm
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
- Feb 13th, 2024 9:45 am
Repare Therapeutics to Regain Global Rights to Camonsertib
- Feb 12th, 2024 9:05 pm
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
- Feb 1st, 2024 3:27 pm
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
- Jan 25th, 2024 12:00 pm
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
- Jan 8th, 2024 12:00 pm
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
- Jan 4th, 2024 9:05 pm
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
- Dec 29th, 2023 9:05 pm
Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why
- Nov 20th, 2023 1:19 pm
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
- Nov 15th, 2023 12:00 pm
Repare Therapeutics Inc. (NASDAQ:RPTX) most popular amongst private equity firms who own 33% of the shares, institutions hold 28%
- Nov 12th, 2023 12:52 pm
These Biotech Stocks Could Double Your Money, According To Analysts
- Nov 9th, 2023 4:38 pm
Repare Therapeutics Inc (RPTX) Reports Q3 2023 Financial Results Amid Pipeline Progress
- Nov 9th, 2023 1:16 pm
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
- Nov 9th, 2023 12:00 pm
Scroll